Drug Trial Radar · NCT06220604
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
731
Actual
Start
Mar 9, 2024
Primary completion
Nov 15, 2024
Study completion Sep 20, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Conditions
- Plaque Psoriasis
Interventions
JNJ-77242113Drug
JNJ-77242113 will be administered orally.
JNJ-77242113 Matching PlaceboDrug
JNJ-77242113 matching placebo will be administered orally.
DeucravacitinibDrug
Deucravacitinib will be administered orally.
Deucravacitinib Matching PlaceboDrug
Deucravacitinib matching placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16Time frame: Week 16
- Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16Time frame: Week 16
Locations
128 sites in 11 countries. Site status is shown where the registry gives one.
Alliance Dermatology and MOHS Center P C
Phoenix, Arizona
California Dermatology & Clinical Research Institute
Encinitas, California
T Joseph Raoof Md Inc
Encino, California
UCSF Fresno
Fresno, California
University of California Los Angeles - Division of Dermatology
Los Angeles, California
Wallace Medical Group, Inc
Los Angeles, California
Dermatologist Medical Group of North County, Inc.
Oceanside, California
Miami Dermatology And Laser Institute
Miami, Florida
Bioclinical Research Alliance Inc.
Miami, Florida
Forcare Clinical Research Inc
Tampa, Florida
Southeast Dermatology Specialists
Douglasville, Georgia
Arlington Dermatology
Rolling Meadows, Illinois
Skin Sciences, PLLC
Louisville, Kentucky
Qualmedica Research
Owensboro, Kentucky
DermAssociates, PC
Rockville, Maryland
Metro Boston Clinical Partners
Brighton, Massachusetts
ActivMed Practices and Research
Methuen, Massachusetts
University of Michigan
Ann Arbor, Michigan
Great Lakes Research Group
Bay City, Michigan
The Derm Institute of West Michigan
Caledonia, Michigan
Hamzavi Dermatology
Canton, Michigan
Somerset Skin Centre
Troy, Michigan
Cleaver Dermatology
Kirksville, Missouri
Bexley dermatology research
Bexley, Ohio
Essential Medical Research
Tulsa, Oklahoma
Oregon Dermatology & Research Center
Portland, Oregon
Paddington Testing Co, Inc.
Philadelphia, Pennsylvania
Clinical Research Center of the Carolinas LLC
Charleston, South Carolina
Palmetto Clinical Trial Services, LLC
Greenville, South Carolina
Arlington Research Center, Inc.
Arlington, Texas
UT Southwestern Medical Center
Dallas, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas
Center for Clinical Studies
Webster, Texas
Cope Family Medicine - Ogden Clinic
Bountiful, Utah
Springville Dermatology CCT Research
Springville, Utah
Kalo Clinical Research
West Valley City, Utah
Virginia Dermatology Skin Cancer Center Pllc
Norfolk, Virginia
The Skin Centre
Benowa, Australia
Monash Medical Centre
Clayton, Australia
Premier Specialists
Kogarah, Australia
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.